Bayforest Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bayforest Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,330	Closed	-$397K	–	805
2025 Q3	$397K	Buy	7,330 +2,978	+68%	+$170K	0.19%	201
2025 Q2	$239K	Sell	4,352 -3,456	-44%	-$204K	0.1%	342
2025 Q1	$552K	Buy	+7,808	New	+$525K	0.24%	139

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bayforest Capital's BMRN Position: Q4 2025 in Review

Bayforest Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 7,330 shares — an estimated $397K sold.

Bayforest Capital first reported a position in BMRN in Q1 2025 and held it in 3 quarters. The position peaked at $552K in Q1 2025. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Bayforest Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Bayforest Capital sold 7,330 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $397K.
Bayforest Capital first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 3 quarters.
Bayforest Capital's BioMarin Pharmaceuticals position peaked at $552K in Q1 2025.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Bayforest Capital's 13F filing for Q4 2025, filed 27 Jan 2026.